Third Quarter 2023 Results

Q3 2023 Media Update

Third Quarter below Prior Year as Expected – Group Outlook Confirmed

  • Group sales of 10.342 billion (Fx & portfolio adj. minus 0.2 percent)
  • EBITDA before special items: 1.685 billion euros (minus 31.3 percent)
  • Sales stable at Crop Science and Pharmaceuticals and up slightly at Consumer Health (Fx & portfolio adj.)
  • Earnings lower at all divisions, especially Crop Science
  • Core earnings per share at 0.38 euros (minus 66.4 percent)
  • Net income at minus 4.569 billion euros, impacted by impairment losses at Crop Science due to interest rates
  • Free cash flow at 1.626 billion euros
  • CEO Anderson: “We are redesigning Bayer to focus only on what’s essential for our mission, ‘Health for all, hunger for none’”
  • Structural options remain under review



Stay tuned and follow us: